Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Anaplastic lymphoma kinase (ALK) gene rearrangements are key drivers in a subset of non-small cell lung cancer (NSCLC).
• The advent of ALK tyrosine kinase inhibitors (TKIs) has revolutionized treatment for ALK-positive NSCLC, offering significant clinical benefits.
• Acquired resistance to first-generation ALK TKIs, such as crizotinib, remains a major challenge, leading to disease progression, particularly in the brain.

Approach:

• This review synthesizes current knowledge on ALK-positive NSCLC, encompassing disease biology and therapeutic strategies.
• It examines the mechanisms of resistance to ALK TKIs and the clinical activity of subsequent-generation inhibitors.
• Focus is placed on treatment options for patients who develop resistance or have brain metastases.

Key Points:

• First-generation ALK TKIs demonstrate high initial efficacy but are often followed by acquired resistance.
• Second- and third-generation ALK TKIs exhibit potent activity against various resistance mutations and are effective in patients with brain metastases.
• Understanding ALK-positive NSCLC biology is crucial for developing and optimizing targeted therapies.

Conclusions:

• ALK-positive NSCLC management has significantly advanced with the development of targeted TKIs.
• Overcoming acquired resistance through next-generation TKIs is critical for improving long-term patient survival.
• Continued research into ALK-driven oncogenesis and resistance mechanisms will further refine therapeutic approaches.